Collaboration to evaluate monoclonal antibody as first-in-class treatment in this settingREDWOOD CITY, Calif.and HOUSTON, Dec.10, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc.("AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, and The University of Texas MD Anderson Cancer Center ("MD Anderson”), today announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer (CRC) and minimal residual disease (MRD) as well as those with MRD in other solid tumors.
"These agreements underscore our commitment to oncology innovation, and we look forward to our collaboration to evaluate AMB-066 in this setting to explore its potential to address a significant unmet medical need.” Minimal residual disease refers to cells remaining after treatment that can cause a relapse of the cancer.
Under the agreements, AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 receptor (CSF1R), in a Phase 2a proof-of-concept study, with patient enrollment anticipated to begin soon.
The story "AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease" has 712 words across 22 sentences, which will take approximately 3 - 6 minutes for the average person to read.
Which news outlet covered this story?
The story "AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease" was covered 2 weeks ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 14 news stories per day.
It's most recent story was published 8 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
